News
ADIL
1.010
-0.98%
-0.010
Adial Pharmaceuticals Advances AD04 with Promising Study Results
TipRanks · 4d ago
Weekly Report: what happened at ADIL last week (1111-1115)?
Weekly Report · 5d ago
Maxim Group Sticks to Their Hold Rating for Adial Pharmaceuticals (ADIL)
TipRanks · 11/15 20:35
Rodman & Renshaw Initiates Coverage of Adial Pharmaceuticals (ADIL) with Buy Recommendation
NASDAQ · 11/15 03:41
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/14 21:10
ADIAL PHARMACEUTICALS SHARES UP 18% ON DATA FOR ALCOHOL ABUSE DRUG
Reuters · 11/14 14:34
Adial Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/14 14:16
BUZZ-Adial Pharma jumps on data for alcohol abuse drug
Reuters · 11/14 14:03
Adial Pharmaceuticals announces topline results from AD04-103 PK study
TipRanks · 11/14 13:55
ADIAL PHARMACEUTICALS : CONTINUED EXCELLENT SAFETY & TOLERABILITY FINDINGS, CONSISTENT WITH EXTENSIVE HUMAN USE EXPERIENCE WITH ONDANSETRON
Reuters · 11/14 13:30
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Benzinga · 11/14 13:00
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 11/14 12:53
Adial Pharmaceuticals Price Target Announced at $8.00/Share by Rodman & Renshaw
Dow Jones · 11/14 12:02
Rodman & Renshaw Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $8
Benzinga · 11/14 11:52
Adial Pharmaceuticals reports Q3 results
Seeking Alpha · 11/13 20:48
Adial Pharmaceuticals expects cash to fund operations into second half of 2025
TipRanks · 11/13 13:36
Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting
TipRanks · 11/12 21:46
Weekly Report: what happened at ADIL last week (1104-1108)?
Weekly Report · 11/11 10:40
Adial Pharmaceuticals Appoints New Chief Financial Officer
TipRanks · 11/05 14:15
Adial Pharmaceuticals Appoints Vinay Shah To Succeed Joseph Truluck As CFO
NASDAQ · 11/05 13:59
More
Webull provides a variety of real-time ADIL stock news. You can receive the latest news about Adial Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ADIL
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.